Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
411 studies found for:    Open Studies | "Uterine Neoplasms"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Uterine Neoplasms"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Epidemiology of Uterine Cancer in Taiwan
Condition: Uterine Cancers
Intervention: Other: Histologic types
2 Recruiting Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix
Conditions: Uterine Cancer;   Cervical Cancer
Intervention: Radiation: Proton radiation therapy
3 Recruiting Targeted Silica Nanoparticles for Image-Guided Intraoperative Sentinel Lymph Node Mapping in Head and Neck Melanoma, Breast and Cervical/Uterine Cancer Patients
Conditions: Head and Neck Cancer;   Melanoma;   Breast Cancer;   Cervical Cancer;   Uterine Cancer
Intervention: Drug: fluorescent cRGDY-PEG-Cy5.5-C dots
4 Recruiting A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
Conditions: Sexual Dysfunctions, Psychological;   Uterine Cervical Neoplasms;   Ovarian Neoplasms;   Uterine Neoplasms;   Genital Neoplasms, Female
Intervention: Behavioral: GyneGals Support Group
5 Unknown  Sentinel Node Biopsy in Endometrial Cancer
Conditions: Uterine Neoplasms;   Sentinel Lymph Node Biopsy
Intervention: Procedure: Sentinel Lymph Node Biopsy
6 Not yet recruiting Sentinel Node Mapping in Women With Cervical and Endometrial Cancer
Conditions: Uterine Cervical Neoplasms;   Uterine Neoplasms
Intervention: Procedure: Sentinel lymph node mapping
7 Not yet recruiting Sentinel Node Mapping in Women With High Risk Endometrial Cancer and Cervical Cancer
Conditions: Uterine Cervical Neoplasms;   Uterine Neoplasms
Intervention: Procedure: SLN mapping and removal of PET-positive lymph nodes
8 Recruiting MRI and Metabolomics Biomarkers for Uterine Malignancy
Condition: Uterine Neoplasms
Intervention:
9 Recruiting Biobehavioral Intervention in Gynecologic Oncology Patients
Conditions: Neoplasms;   Ovarian Neoplasms;   Uterine Neoplasms;   Vulva
Intervention: Behavioral: BBI intervention
10 Recruiting Colony-Stimulating Factor-1 (CSF-1) and Other Cytokines in Human Endometrial Carcinogenesis
Conditions: Uterine Neoplasms;   Endometrial Neoplasms
Intervention:
11 Recruiting The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection
Condition: Uterine Cancer
Interventions: Drug: Dexmedetomidine group;   Drug: Control group
12 Recruiting Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
Conditions: Advanced Malignant Neoplasm;   Cervical Squamous Cell Carcinoma;   Endometrial Carcinoma;   Malignant Uterine Neoplasm;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Head and Neck Carcinoma;   Recurrent Malignant Neoplasm;   Recurrent Ovarian Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Renal Cell Carcinoma;   Solid Neoplasm;   Stage III Bladder Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Cervical Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Breast Cancer;   Stage IV Ovarian Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Bladder Cancer;   Stage IVA Cervical Cancer;   Stage IVB Bladder Cancer;   Stage IVB Cervical Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Nanoparticle Albumin-Bound Rapamycin;   Other: Quality-of-Life Assessment
13 Recruiting The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
Conditions: Bladder Cancer;   Colorectal Cancer;   Endometrial Cancer;   Kidney Cancer;   Skin Cancer;   Uterus Cancer
Intervention: Behavioral: Health and Diet Questionnaire
14 Recruiting A Mind-body Intervention to Improve Body and/or Self Image
Conditions: Breast Cancer;   Ovarian Cancer;   Uterine Cancer;   Cervical Cancer
Interventions: Behavioral: Hypnotic Relaxation Therapy;   Behavioral: Progressive Muscle Relaxation
15 Recruiting A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping
Conditions: Endometrial Cancer;   Uterine Cancer;   Cervical Cancer
Intervention: Device: PINPOINT
16 Recruiting Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.
Conditions: Ovarian Cancer;   Cervical Cancer;   Uterine Cancer;   Anemia
Interventions: Other: Oral Ferrous Fumarate;   Other: Placebo
17 Recruiting Cancer of the Uterus and Treatment of Stress Urinary Incontinence
Conditions: Endometrial Cancer;   Stress Urinary Incontinence
Intervention:
18 Recruiting Prospective Analysis of Robot-Assisted Surgery
Conditions: Esophageal Cancer;   Gastric Cancer;   Pancreatic Cancer;   Rectal Cancer;   Bladder Cancer;   Prostate Cancer;   Renal Cancer;   Uterus Cancer;   Head and Neck Cancer;   Lung Cancer
Interventions: Procedure: Robot-assisted surgery;   Procedure: Conventional Surgery
19 Not yet recruiting Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer
Conditions: Cervical Cancer;   Ovarian Cancer;   Uterine Cancer;   Vaginal Cancer;   Vulval Cancer;   Psychosexual Dysfunctions
Intervention: Behavioral: SAFFRON stepped care
20 Recruiting Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer;   Uterine Cancer;   Mesotheliomas;   Gastrointestinal Cancers;   Cervical Cancer
Interventions: Device: HIPEC: MMC 30mg @ T0, 10mg @ T45min;   Device: HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0;   Device: HIPEC: CDDP 75 mg/m2 @T0;   Device: HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years